289 related articles for article (PubMed ID: 37724564)
1. An updated meta-analysis on the efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor treatment of anemia in nondialysis-dependent chronic kidney disease.
Zhao H; Li P; Zhang HL; Jia L
Ren Fail; 2023; 45(2):2258986. PubMed ID: 37724564
[TBL] [Abstract][Full Text] [Related]
2. Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients.
Wang B; Yin Q; Han YC; Wu M; Li ZL; Tu Y; Zhou LT; Wei Q; Liu H; Tang RN; Cao JY; Lv LL; Liu BC
Ren Fail; 2020 Nov; 42(1):912-925. PubMed ID: 32869703
[TBL] [Abstract][Full Text] [Related]
3. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors
Yang J; Xing J; Zhu X; Xie X; Wang L; Zhang X
Front Endocrinol (Lausanne); 2023; 14():1131516. PubMed ID: 37008953
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia inducible factor-prolyl hydroxylase inhibitors in anemic patients with non-dialysis dependent chronic kidney disease: a meta-analysis of randomized clinical trials.
Mohamed MMG; Oyenuga M; Shaikh S; Oyenuga A; Kheiri B; Nwankwo C
Int Urol Nephrol; 2023 Jan; 55(1):167-171. PubMed ID: 35852713
[TBL] [Abstract][Full Text] [Related]
5. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors.
Sugahara M; Tanaka T; Nangaku M
Pharmacol Ther; 2022 Nov; 239():108272. PubMed ID: 36031160
[TBL] [Abstract][Full Text] [Related]
6. Cardiac and Kidney Adverse Effects of HIF Prolyl-Hydroxylase Inhibitors for Anemia in Patients With CKD Not Receiving Dialysis: A Systematic Review and Meta-analysis.
Zheng Q; Wang Y; Yang H; Sun L; Zhang P; Zhang X; Guo J; Liu YN; Liu WJ
Am J Kidney Dis; 2023 Apr; 81(4):434-445.e1. PubMed ID: 36396085
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
Mima A
Eur J Pharmacol; 2021 Dec; 912():174583. PubMed ID: 34678238
[TBL] [Abstract][Full Text] [Related]
8. A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease.
Chen J; Shou X; Xu Y; Jin L; Zhu C; Ye X; Mei Z; Chen P
Aging (Albany NY); 2023 Mar; 15(6):2237-2274. PubMed ID: 36988549
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
Souza E; Cho KH; Harris ST; Flindt NR; Watt RK; Pai AB
Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment of chronic kidney disease patients with anemia using hypoxia-inducible factor prolyl hydroxylase inhibitors: potential concerns.
He J; Jia Z; Zhang A; Bai M
Pediatr Nephrol; 2024 Jan; 39(1):37-48. PubMed ID: 37284874
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis.
Zheng Q; Yang H; Sun L; Wei R; Fu X; Wang Y; Huang Y; Liu YN; Liu WJ
Pharmacol Res; 2020 Sep; 159():105020. PubMed ID: 32561478
[TBL] [Abstract][Full Text] [Related]
12. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
Del Vecchio L; Locatelli F
Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) on anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD): a systematic review and meta-analysis.
Zhang S; Guo J; Xie S; Chen J; Yu S; Yu Y
Int Urol Nephrol; 2021 Jun; 53(6):1139-1147. PubMed ID: 33026571
[TBL] [Abstract][Full Text] [Related]
14. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Therapy for Anemia in Renal Transplantation Patients by Prior Erythropoiesis Stimulating Agent Use.
Nakamura N; Aso S; Nakagawa C; Tachibana M; Fujikawa A; Tsubouchi K; Gunge N; Miyazaki T; Okabe Y; Matsuzaki H; Matsuoka H; Haga N
Transplant Proc; 2023 May; 55(4):829-831. PubMed ID: 37105829
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
Kurata Y; Tanaka T; Nangaku M
Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):414-422. PubMed ID: 32452915
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors vs. Erythropoietin-Stimulating Agents in Treating Anemia in Renal Patients (With or Without Dialysis): A Meta-Analysis and Systematic Review.
Damarlapally N; Thimmappa V; Irfan H; Sikandari M; Madhu K; Desai A; Pavani P; Zakir S; Gupta M; Khosa MM; Kotak S; Varrassi G; Khatri M; Kumar S
Cureus; 2023 Oct; 15(10):e47430. PubMed ID: 38021836
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-inducible factor prolyl hydroxylase inhibitors for anemia in heart failure patients: A protocol for systematic review and meta-analysis.
Fukuta H; Hagiwara H; Kamiya T
PLoS One; 2022; 17(9):e0275311. PubMed ID: 36170343
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in maintenance dialysis: a meta-analysis.
Wu M; Zang C; Ma F; Chen B; Liu J; Xu Z
Clin Exp Nephrol; 2022 Nov; 26(11):1043-1054. PubMed ID: 36006596
[TBL] [Abstract][Full Text] [Related]
20. [Renal anemia and hypoxia-inducible factor prolyl hydroxylase inhibitor].
Maruno S; Tanaka T; Nangaku M
Rinsho Ketsueki; 2021; 62(5):371-377. PubMed ID: 34108317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]